Want to join the conversation?
$VRTX said it plans to submit a Marketing Authorization Application (MAA) variation in European Union in 1H17 for children ages 6 through 11 who have two copies of F508del mutation. This application will be based on data from Phase 3 efficacy study with primary endpoint of absolute change in lung clearance index (LCI).
No better outlook on $MSFT. Even if the results beat a bit, the stock may move 4 to 6% higher, but won't go above $60.